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Abstract
Introduction—Prior clozapine studies indicated no effects, mild inhibition or induction of 
valproic acid (VPA) on clozapine metabolism. The hypotheses that 1) VPA is a net inducer of 
clozapine metabolism, and 2) smoking modifies this inductive effect were tested in a therapeutic 
drug monitoring study.
Methods—After excluding strong inhibitors and inducers, 353 steady-state total clozapine 
(clozapine plus norclozapine) concentrations provided by 151 patients were analyzed using a 
random intercept linear model.
Results—VPA appeared to be an inducer of clozapine metabolism since total plasma clozapine 
concentrations in subjects taking VPA were significantly lower (27% lower; 95% confidence 
interval, 14% to 39%) after controlling for confounding variables including smoking (35% lower, 
28% to 56%).
Discussion—Prospective studies are needed to definitively establish that VPA may 1) be an 
inducer of clozapine metabolism when induction prevails over competitive inhibition, and 2) be an 
inducer even in smokers who are under the influence of smoking inductive effects on clozapine 
metabolism.
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INTRODUCTION
The pharmaceutical company that developed clozapine has published very limited 
information on clozapine metabolism [1]; most of our knowledge is limited to the N-
demethylation of clozapine to norclozapine [2]. Also, there is limited information on the 
metabolism to clozapine-N-oxide, which is partially accounted for by flavin-containing 
monooxygenase (FMO) [3], and on the metabolism to the glucuronides by the UDP 
glucuronosyltransferases (UGTs) [4]. In average subjects not exposed to inducers or 
inhibitors and not having unusual genetic profiles, it is currently believed that clozapine is 
mainly metabolized by CYP1A2, with lesser roles for CYP2C19, CYP3A4 and CYP2D6 
[2]. A recent study suggested that CYP2C19 may have a greater role in clozapine 
metabolism than expected since CYP2C19 poor metabolizers have increased plasma 
clozapine and norclozapine concentrations [5].
Fluvoxamine is a powerful inhibitor of clozapine metabolism [6]. This is not surprising 
since fluvoxamine is a strong CYP1A2 inhibitor, but other CYP inhibition may be relevant 
to clozapine metabolism since fluvoxamine is also a strong inhibitor of CYP2C19, a 
moderate inhibitor of CYP2C9 and CYP3A4, and a weak inhibitor of CYP2D6 [7]. 
Fluvoxamine inhibitory effects may vary from individual to individual, with increases in 
clozapine concentrations up to five to ten times [2,8]. A recent study indicates that saturation 
of CYP inhibition may occur with plasma fluvoxamine concentrations in the range of 50–
150 ng/ml [5]. Therefore, interindividual variation in serum clozapine concentrations in 
patients taking fluvoxamine is probably explained by the different plasma fluvoxamine 
concentrations, and by different CYP genotypes which contribute to a different relevance of 
CYP1A2 versus non-CYP1A2 inhibitory pathways of clozapine metabolism. Paroxetine and 
fluoxetine are mild inhibitors of clozapine metabolism but they can be detected by 
controlling confounding variables [6,7]. Ciprofloxacin is another clinically relevant 
CYP1A2 inhibitor that can decrease clozapine metabolism [8].
Smoking and some antiepileptic drugs including carbamazepine, phenytoin and 
phenobarbital are powerful clozapine inducers [2,8–10]. The different enzymes involved in 
clozapine metabolism have different levels of vulnerability to induction. Concerning CYP 
isoforms, CYP2D6 cannot be induced. CYP2C19 is less susceptible to inductive effects than 
CYP3A4 [11]. The limited information available comparing CYP1A2 versus CYP3A4 
induction indicates that carbamazepine has greater effects on CYP3A4 substrates than on 
CYP1A2 substrates [12]. In summary, there is a limited understanding of the relative role of 
different enzymes on clozapine metabolism in situations of induction but the different levels 
of CYP1A2, CYP2C19, CYP3A4 and UGT inductions are probably relevant. The lack of 
drug-drug interaction (DDI) studies on how inducers change the relative role of different 
enzymes is a gap not only in clozapine research but in all drugs research [13].
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Due to our limited knowledge of clozapine metabolism and the assumption that in most 
circumstances and most patients norclozapine is the main clozapine metabolite, it is not 
surprising that most therapeutic drug monitoring (TDM) studies have focused on plasma 
clozapine and norclozapine concentrations [14]. Prior studies [15,16] suggest that total 
plasma clozapine concentration, calculated by adding plasma clozapine and norclozapine 
concentrations, may be a better indicator of overall clozapine metabolism than plasma 
clozapine concentration alone. Obviously a better total clozapine concentration would also 
include the plasma concentrations of clozapine-N-oxide and glucuronides. Total plasma 
concentrations as defined in this article (by adding clozapine and norclozapine) are 
influenced by inducers and inhibitors in a way that is consistent with known 
pharmacological mechanisms [15,16]. Similarly, the norclozapine/clozapine ratio has 
occasionally been used in the literature, but this ratio: 1) is not a good measure of CYP1A2 
activity [17], and 2) has very high within-subject variability, even under the same clozapine 
dose [18]. CYP1A2 contributes to the simultaneous formation and destruction of 
norclozapine while other CYPs and renal elimination contribute to norclozapine elimination 
[19–21]. Using a norclozapine/dose ratio makes little sense from a pharmacological point of 
view because it is difficult to quantitatively predict how increments or reductions in 
CYP1A2 activity influence this ratio.
Valproic acid (VPA) is metabolized by UGTs (40%), and by β-oxidation as a fatty acid 
(30%), with minor CYP-dependent metabolism (including CYP2C9, CYP2C19 and 
CYP2A6). At low doses, β-oxidation may be the most important pathway, while at 
therapeutic doses glucuronidation may be more important [22]. Until 2008 (see Table 1 for a 
study review) [23–29], the literature had provided contradictory results concerning the 
effects of VPA on clozapine metabolism. Studies with different designs indicated no effects 
[23,26,28], mild inhibition [26,29] or mild induction [24,25,27]. In 2008, Diaz et al [16] 
developed a statistical random-effects linear model using an Italian clozapine sample that 
combined unpublished TDM data (N=83) with data from several published DDI studies 
(N=172), including one study focused on concomitant VPA treatment [26]. After adjusting 
for potential confounding variables (Table 1), VPA appeared to have inhibitory effects in 
non-smokers whereas VPA appeared to induce clozapine metabolism in smokers. Based on 
this finding, Diaz et al. [16] proposed that VPA may have differential effects on plasma 
clozapine concentrations depending on whether or not the patient is a smoker. The VPA-
clozapine DDI is probably very complex. Besides the issue of VPA exhibiting both 
inductive and inhibitory effects on clozapine metabolism, another finding of the Italian 
clozapine TDM study [16] was that VPA appeared to potentiate smoking inductive effects 
on clozapine metabolism since smoking alone produced a 20% reduction in plasma 
clozapine concentrations [95% confidence interval CI, (−31, −7)], whereas smoking and 
VPA together produced a 41% reduction (−56, −21).
The lack of smoking control in study designs may explain the inconsistent results from prior 
studies of VPA and clozapine metabolism. In a recent case report of a smoker [30], the 
inductive VPA’s effects appeared to be dose-related.
Traditionally, VPA has been considered a broad-spectrum metabolic enzyme inhibitor 
because 1) it inhibits UGT enzymes (UGT1A4 and UGT2B7), 2) it competitively inhibits 
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CYP2C9, and 3) it weakly inhibits CYP2C19 and CYP3A4 [22,31–33] (Table 2). On the 
other hand, progressively more literature [34–39] indicates that in the right circumstances 
VPA can have net inductive effects (Table 2). VPA may not be the only case. This is 
obviously a complex situation since oxcarbazepine or topiramate can have net inhibitory 
effects, net inducer effects or no net effects for the same specific substrate. As an example, 
topiramate in low doses may be a mild inducer of VPA metabolism but, at high doses, it 
may be an inhibitor [40]. These complex effects depend on the specific metabolism 
mechanisms, and are frequently influenced by the dosing of the drug that has a mixed 
inhibitor-inducer profile [41,42].
When discussing VPA effects on clozapine metabolism, some lessons can be learned by 
paying attention to olanzapine which has a metabolic pathway similar to that of clozapine 
[2,8]. Olanzapine appears to be mainly metabolized by CYP1A2 and UGT [2,8]. Although 
the VPA-olanzapine DDI has not been well studied [43], it is important to note that three 
studies with different designs indicated that VPA may be an olanzapine inducer [37–39]. 
Moreover, one of these three VPA-olanzapine studies used a prospective design [39] that 
indicated that, in reality, VPA may have a mixed profile: VPA may have the potential of 
being both an inhibitor and inducer of olanzapine metabolism. In fact, VPA exhibits net 
inhibiting effects, net inductive effects or no net effects, depending on VPA concentrations. 
At low VPA concentrations, VPA appeared to be an olanzapine competitive inhibitor, and at 
higher VPA concentrations VPA inductive effects appeared to overcome its competitive 
inhibitory effects [see Table 2, footnote g].
In this study, we examined the hypotheses generated in the Italian clozapine study that, 
under some conditions, VPA may be a net inducer of clozapine metabolism, and that 
smoking may modify this inductive effect, using a sample of Swiss patients on clozapine 
TDM. It is a well-established fact that smoking is an inducer of clozapine metabolism but in 
this study we also searched for a confirmation of the new finding that the inductive effects 
of smoking may be augmented by VPA treatment.
MATERIAL AND METHODS
Subjects
This study examined the data of 158 patients who both were on clozapine treatment, and 
provided measurements of trough steady state plasma clozapine and norclozapine 
concentrations for TDM during their treatment, at the Hospital of Cery, University of 
Lausanne, Switzerland. Trough concentrations were defined as those measured after a time 
≥10 hours but ≤24 hours elapsed from last clozapine dose. This is a sample of participating 
patients who provided data for clinical purposes. The Lausanne University Hospital has the 
general permission from its institutional review board to use for research purposes 
anonymized data collected in routine clinical work.
Laboratory analysis
Samples were analyzed for plasma clozapine and norclozapine concentrations, measured in 
ng/mL, by high performance liquid chromatography-mass spectrometry (HPLC-MS) using a 
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previously published method [44]. Plasma VPA concentrations were obtained by using 
Fluorescence Polarization Immunoassays (Cobas Integra® 400 Plus, Roche).
Samples
Total clozapine concentrations, defined as the sum of trough steady state plasma clozapine 
and norclozapine concentrations, were computed. Any available total clozapine 
concentration was used for the current study if and only if it satisfied two criteria: 1) 
complete information on clozapine dose, comedications and smoking status was on record at 
the time the concentration was obtained; and 2) the concentration was obtained at a time 
when the patient was not taking a known well-established inducer [2,8,10] or inhibitor 
[2,8,10,16] of clozapine metabolism. A total of 353 total clozapine concentrations, provided 
by 151 of the 158 patients satisfied both of the above two criteria, and these are the 
observations analyzed in this article. The number of plasma clozapine concentrations 
excluded due to co-prescription of well-established inducers was 2 (both under 
carbamazepine), and due to well-established inhibitors was 12 (fluvoxamine, 3; fluoxetine,5; 
paroxetine, 2; and ciprofloxacin, 2). Blood samples from patients taking strong inducers or 
inhibitors at the moment of sampling were excluded due to their small numbers and because 
there were uneven distributions of well-established inducers and inhibitors across groups 
with and without VPA.
The average number of total clozapine concentrations provided by the 151 subjects was 2.3, 
and each subject provided from 1 to 27 total concentrations. Forty-eight percent (73/151) of 
the patients were males (they provided a total of 167 total plasma clozapine concentrations); 
48% (73/151) were smokers (178 concentrations); and 19% (28/151) of the patients 
provided total clozapine concentrations under VPA (102 concentrations).
Total plasma clozapine concentrations were classified into whether or not they were 
measured under a potential mild inhibitor of clozapine metabolism (see Table 3, footnote a) 
[2,8,10,16, 45], and also into whether or not they were measured under a potential mild 
inducer of clozapine metabolism (Table 3, footnote a) [2,8,10,16,45]. Fifty-five of the 353 
investigated total plasma clozapine concentrations were measured when the patient was 
taking at least one potential mild inhibitor; these 55 measures belonged to 31 patients. Also, 
55 total plasma clozapine concentrations, which belonged to 23 patients, were measured 
under at least one potential mild inducer.
Statistics
A random intercept linear model of the log of total plasma clozapine concentrations was 
built, similar to the model used by Diaz et al. [16]. This model has been found to represent 
very accurately the steady-state measures of a substantial number of drugs and patient 
samples [46–49]. The model was built by using all 353 investigated total plasma clozapine 
concentrations. The dependent variable of the model was the log of total plasma clozapine 
concentration, and the log of clozapine dose was included as an independent variable. Other 
independent variables examined were male gender (1=male, 0=female), smoking 
(1=smoker, 0=non-smoker), taking VPA (1=taking, 0=not taking), taking potential mild 
inhibitors of clozapine metabolism (1=taking, 0=not taking), taking potential mild inducers 
Diaz et al. Page 5
Pharmacopsychiatry. Author manuscript; available in PMC 2014 November 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
of clozapine metabolism (1=taking, 0=not taking), and weight (in Kg). The interaction 
between smoking and taking VPA, defined as the mathematical product of the variables 
smoking and taking VPA, was also examined as a possible term of the model. Covariate 
effect sizes were computed as in Diaz et al. [16] and their interpretation is further explained 
in Diaz et al. [48]. A negative effect size indicates induction of clozapine metabolism, and a 
positive effect size indicates inhibition, with greater effect sizes in absolute value indicating 
induction or inhibition, respectively. The final model reported in Table 3 fitted well 
according to residual analyses.
An additional random intercept linear model of the log of total plasma clozapine 
concentrations was built by using only concentrations that were measured when 1) the 
patient was taking VPA and provided a measurement of plasma VPA concentration and 2) 
the patient was not taking any well-established inhibitor or inducer of clozapine metabolism. 
A total of 51 total plasma concentrations provided by 18 subjects satisfied this condition and 
was therefore used to fit this second model. In addition to the log of clozapine dose, this 
model also included plasma VPA concentrations (in μg/mL) as an independent variable. 
Other variables examined as potential independent variables of this model were weight and 
smoking, as well as the interaction between smoking and VPA plasma concentrations which 
was defined as the product of the two variables.
RESULTS
Variables influencing total plasma clozapine concentrations
Table 3 shows the obtained model of total plasma clozapine concentrations built with all 353 
concentrations. Gender, taking VPA, smoking, and clozapine dosage affected significantly 
total clozapine concentrations (Table 3). After adjusting for these significant variables, the 
following variables did not significantly affect total clozapine concentrations and were not 
included in the final model: body weight, taking potential mild inhibitors of clozapine 
metabolism, and taking potential mild inducers of clozapine metabolism (Table 3). After 
controlling for potential confounders, subjects taking VPA had significantly lower total 
plasma clozapine concentrations than patients not taking VPA (p<0.001). Specifically, total 
plasma clozapine concentrations in patients taking VPA were significantly lower than those 
in patients not taking it (27% lower; Table 3). Also, after controlling for potential 
confounders, total plasma clozapine concentrations in smokers were significantly lower than 
in non-smokers (35% lower; Table 3).
After adjusting for gender and clozapine dosage, there was not a significant interaction 
between smoking and taking VPA (p=0.7). Therefore, taking VPA did not significantly 
modify the effect of smoking on total plasma clozapine concentrations, and smoking did not 
significantly modify the effect of VPA.
Variables affecting total plasma clozapine concentrations in patients taking VPA
In the model for 18 patients taking VPA who provided VPA levels, only clozapine dose had 
a significant effect on total plasma clozapine concentrations (p<0.001). None of the other 
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independent variables in this model, including gender, weight, VPA levels and smoking 
were significant.
DISCUSSION
Can VPA be an inducer of clozapine metabolism?
The results from the total sample suggest that VPA may be an inducer of clozapine 
metabolism since, after controlling for potential confounders, total plasma clozapine 
concentrations in subjects taking VPA were significantly lower than those in patients not 
taking it (Table 3).
Can VPA also be a competitive inhibitor of clozapine metabolism?
Table 4 compares the results of the current study with our prior study which used an Italian 
sample [16]. An inconsistency appears to exist since the Italian sample appeared to indicate 
that VPA may be an inhibitor in non-smokers and an inducer in smokers, whereas the Swiss 
sample appears to suggest that VPA is only an inducer regardless of smoking status.
Unfortunately this Swiss study and the prior Italian study did not control for the duration of 
VPA treatment. Time may also be an important variable to control for, as suggested by the 
VPA-olanzapine study [39], because the relative importance of the inhibitory and inductive 
effects of VPA may change over time before steady state for both induction and competitive 
inhibition is reached. On the other hand, the Italian sample [16] provided only 
“circumstantial” evidence that VPA may also be a competitive inhibitor. VPA plasma 
concentrations and smoking may both interact to determine whether VPA effects are 
inductive or inhibitory on clozapine metabolism. So, it is possible that uncontrolled and 
unbalanced time effects on induction and inhibition may have contaminated the data in both 
samples.
Can VPA modify the inductive effects of smoking on clozapine metabolism?
The Italian study [16] indicated the possibility that VPA may potentiate the inductive effects 
of smoking, since the negative effect size of smoking on plasma clozapine concentrations in 
patients taking VPA (−41%) was significantly greater in absolute value than that in patients 
not taking VPA (−20%) (Table 4). In the total Swiss sample, the average effect size of 
smoking was −35%, but no significant difference was observed between patients taking and 
not taking VPA regarding this effect size. Therefore, the Swiss sample demonstrated that 
VPA had an inductive effect in smokers beyond smoking inductive effects, but did not 
replicate the result of the Italian study that there is an interaction between smoking and 
taking VPA. In particular, the current study did not confirm that VPA may potentiate the 
inductive effects of smoking.
Gender
In our prior US clozapine study [46] using a random intercept linear model, male gender 
was associated with higher drug clearance. A similar result was obtained in the Swiss study 
described in this article. It is possible that female sexual hormones may contribute to 
decrease clozapine metabolism. Certainly, oral contraceptives appear to be inhibitors of 
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clozapine metabolism [50, 51] and their use was most likely underreported in these TDM 
patients.
Limitations
The major limitation of this study is that this is not a prospective study designed to test 
whether or not VPA is an inducer of clozapine metabolism. The Swiss investigators 
collected this sample for clinical purposes and were unaware of the hypotheses suggested by 
the Italian clozapine study [16] and the prospective VPA-olanzapine study [39]. However, 
this lack of influence of the hypotheses on data collection may have its positive side of not 
biasing the collection procedures.
In our study, the number of total clozapine concentrations provided on any patient varied 
from 1 to 27. The statistical model used in this study, a mixed model, is known to very 
efficiently separate inter- and intra-patient variabilities [48] and to appropriately handle 
different numbers of observations across subjects [52]. Thus, it is not expected a priori that 
the different observations across subjects biased the estimates of model parameters and, 
therefore, our conclusions. On the other hand, we have to acknowledge that the lack of 
enough repeated measures of clozapine concentrations from patients taking VPA before and 
after starting VPA probably reduced the model’s ability to detect both VPA’s inductive 
effects and a possible interaction between VPA and smoking, interaction that was found in 
the Italian sample [16]. Moreover, the larger the number of available repeated measures, the 
more likely the mixed model will be able to control for the noise introduced by inter- and 
intra-patient variability. This gives us confidence in the results reported in Table 3, since our 
study used 353 observations from 151 patients. In a relatively large naturalistic sample like 
this one, however, we can expect to find unusual results due to lack of compliance, unusual 
genetic profiles and/or laboratory errors. Although standard residual analyses did not 
identify outliers in our data, we cannot rule out the existence of some of these issues.
The lack of availability of plasma clozapine-N-oxide concentrations is unfortunate. The 
conversion of clozapine to clozapine-N-oxide is probably mainly explained by CYP3A4 and 
FMO3 [3], and is reversible [53]. The possible influence of VPA inhibition and/or induction 
on clozapine oxidation to clozapine-N-oxide has not been studied. On the other hand, a 
study of the major FMO3 polymorphism in Caucasians found no clinically relevant effects 
on clozapine metabolism [54]. As indicated in the introduction, CYP1A2 contributes to the 
simultaneous formation and destruction of norclozapine. This implies that using 
norclozapine/dose ratios measured during routine TDM may not help to disentangle these 
two simultaneous processes. In fact, a controlled, non-observational longitudinal design may 
be needed to build a dynamic pharmacological model of these processes. Weekly repeated 
measures in the same patients under controlled conditions, as well as baseline measures 
prior to VPA treatment, would be required to establish VPA greater or lower inductive 
effects on clozapine versus norclozapine.
Any TDM clozapine study is limited by the complete lack of control of variables. Intake of 
St. John’s wort was not recorded. St. John’s wort is not expected to have major inductive 
effects on clozapine since it is not an inducer of theophylline, a CYP1A2-dependent drug, 
but it may have minor effects since it is described as an inducer of CYP2C9, CYP2C19 and 
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CYP3A4 [55]. In the other hand some potential clinically-relevant clozapine inhibitors such 
as caffeine intake [8] and presence of inflammation [8,15] were not assessed in this Swiss 
TDM study. The other side of the coin is that if we were able to detect the VPA effect using 
this type of design, it means that the effect should be strong enough to influence clinical 
practice.
Ideally, one would like to use a prospective design that disentangles the effect of valproate 
treatment duration, as in the prospective study of the effects of VPA on olanzapine 
metabolism [39]. That elegant prospective study [39] established that VPA is an inducer of 
olanzapine metabolism and provided important clues indicating that VPA may also be a 
competitive inhibitor of olanzapine metabolism that is dependent on VPA levels. 
Interestingly, our statistical approach did not demonstrate an inductive effect of VPA 
treatment on olanzapine metabolism when reanalyzing Italian olanzapine data from TDM 
and DDI studies that included 163 patients who provided 360 plasma samples [56]. In 
contrast, the relatively small prospective VPA-olanzapine study with 18 patients and 3 
samples per patient did demonstrate it [40].
Clinical investigators do not have the abundant resources of pharmaceutical companies to 
complete large prospective studies lasting for several months. A pharmaceutical company 
has completed many well-controlled randomized clinical trials combining VPA and 
clozapine but has never looked into possible DDIs between these two products [43]. The 
Italian sample and this Swiss clozapine sample had limitations and provided just 
“circumstantial” evidence supporting the hypothesis of an inductive effect of VPA on 
clozapine metabolism, but these were relatively inexpensive studies with no external 
funding for data collection. The use of a sophisticated statistical random-effects linear model 
[45–48] has converted these inexpensive and unfunded collected samples into great 
opportunities to explore new and revolutionary ideas about DDIs between clozapine and 
VPA.
Ideally, a prospective randomized study on the effects of VPA on clozapine metabolism 
should: 1) stratify by smoking status; 2) provide a comprehensive measure of clozapine 
pharmacokinetics including at least clozapine, norclozapine and clozapine-N-oxide 
concentrations and even consider glucuronidation metabolites; and 3) provide a 
comprehensive measure of VPA pharmacokinetics, including at least total and free VPA and 
albumin concentrations. This extensive pharmacological information may help to identify 
the pharmacological mechanism involved in the VPA inductive and/or inhibitory effects on 
clozapine metabolism. Until that study is completed one can hypothesize that VPA inductive 
and competitive inhibitory effects may be mediated through UGTs since VPA is partly 
metabolized by UGTs and is definitively an inhibitor of some UGTs. VPA is not known to 
induce or competitively inhibit CYP1A2. VPA may be only a mild inhibitor of CYP2C19 
and CYP3A4, and is not thought to be an inducer. There are no studies of VPA effects on 
FMO metabolism.
Conclusion
The Italian clozapine study results [16], the partial replication of these results using the 
current Swiss sample, and other clozapine [24,25,27,30] and pharmacokinetic literature [34–
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39] suggest that VPA may be an inducer of some metabolic pathways and, in particular, of 
clozapine metabolism. Prospective studies are needed to definitively establish this 
hypothesis. Prospective studies need to consider that it is possible that VPA may also be a 
competitive inhibitor of clozapine metabolism [16, 42]. The net effect of VPA on clozapine 
metabolism may be the result of a combination of these two opposite drug metabolic actions, 
induction and inhibition, and may be influenced by smoking status and VPA levels, and 
possibly by VPA treatment duration. This study also highlights the importance of controlling 
for smoking and VPA levels in order to compare two different studies of the effects of VPA 
on clozapine metabolism.
A second new idea supported by the Italian [16] and the Swiss samples is that VPA may be 
an inductor in clozapine patients whose clozapine metabolism has already been induced by 
smoking. Other studies need to replicate this hypothesis, too.
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Table 2
Review of non-clozapine literature on VPA inhibitory versus inductive effects.
INHIBITORY EFFECTS
Traditional view [31,32] VPA inhibitory at CYP2C9, UGTs and epoxide hydroxilase
More recent [33] Inhibitor for paliperidone clearance:a unknown mechanism
INDUCTIVE EFFECTS
Prospective volunteer study [34]b Mild auto-inducer of its own metabolism at low doses
In vitro study [35] Inducer of CYP3A4 and P-glycoprotein gene expression
Prospective patient study [36]c Inducer of aripiprazole metabolismd
Case series [37]e Inducer of olanzapine metabolism
Therapeutic drug monitoring [38]f Inducer of olanzapine metabolism
INDUCTIVE AND INHIBITORY EFFECTS
Prospective study [39] Net inducer of olanzapine metabolism
But can behave as net inhibitor in low VPA concentrations
VPA concentration, time and smoking influence net effectsg
VPA= valproic acid.
a
This pharmaceutical company study has not been published. The prescribing information [30] described that co-administration of a single 
paliperidone dose of 12 mg with divalproex sodium extended-release tablets (two 500 mg tablets once daily) resulted in an increase of 
approximately 50% in the peak concentration and area under the curve of paliperidone. No pharmacological mechanism is provided to explain this 
inhibition.
bA prospective clinical study [34] in 12 young male volunteers taking low VPA doses for 3 weeks, reporting that VPA may induce its own 
metabolism by inducing β-oxidation.
cA pharmaceutical company prospective study [36] in 10 patients treated with VPA for 3 weeks. VPA appeared to be a mild inducer of aripiprazole 
metabolism. There was a decrease of 26% in the aripiprazole peak concentration and of 24% in the aripiprazole area under the curve with minimal 
effects on the active metabolite of aripiprazole.
dAlthough the mechanism of VPA inductive effects on aripiprazole are not well understood, induction of p-glycoprotein may be a possible 
mechanism [10].
eA case series of four patients stabilized on olanzapine concluding that VPA decreased olanzapine levels by 50% [37].
fA large olanzapine TDM study included 92 VPA patients with 166 plasma olanzapine concentrations and 205 control patients with 247 plasma 
olanzapine concentrations. The olanzapine concentration/dose ratio decreased by 32% indicating that VPA is a mild olanzapine inducer [38].
gA prospective study [40] in 18 patients that found that higher VPA plasma concentrations were associated with statistically significant, small 
decreases in plasma olanzapine concentrations that depended on VPA treatment duration (2 or 4 weeks). Findings at the 4th treatment week 
indicated that VPA, besides inducing olanzapine metabolism, may also be a competitive inhibitor. At low VPA concentrations VPA appeared to be 
an olanzapine competitive inhibitor, and at higher VPA concentrations VPA inductive effects appear to overcome its competitive inhibitory effects. 
The VPA concentration that led to change from net inhibitory effects to net inductive effects was different in smokers and non-smokers. By using 
the statistical model developed in this olanzapine study [37], the VPA concentrations producing a sufficiently high inductive effect on olanzapine 
metabolism that compensates for VPA inhibitory effects can be predicted for week 4. Specifically, 1) if the patient is a 40-year-old smoker taking 
10 mg/day of olanzapine, a VPA level of 13.3 μg/mL at week 4 (usual therapeutic ranges for epilepsy are 50–100 μg/mL and for mania 50–125 
μg/mL) will neutralize VPA inhibitory effects, and higher VPA concentration will produce a net induction of olanzapine metabolism at week 4. 
And 2) if the patient is a comparable non-smoker, the neutralization will occur at VPA concentrations of 41.8 μg/mL, with a net induction 
occurring at higher levels.
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